“Non-Trippy” Magic Mushrooms: New Compounds Offer Therapeutic Potential Without Hallucinations

Scientists are making strides in harnessing the therapeutic potential of psilocybin, the psychoactive compound in “magic mushrooms,” while minimizing the unwanted hallucinogenic effects. Recent research published in ACS’ Journal of Medicinal Chemistry details the creation of modified psilocin molecules that maintain biological activity but produce fewer psychedelic-like responses.

The Promise of Psilocybin and the Challenge of Hallucinations

Psilocybin is gaining attention for its potential to treat neuropsychiatric conditions, including depression, anxiety, substance use disorders, and certain neurodegenerative diseases . However, the intense hallucinogenic effects associated with the compound have presented a barrier to its widespread medical use.

Engineering Modified Psilocin Derivatives

Researchers focused on psilocin, the active form of psilocybin when processed by the body. A team led by Sara De Martin, Andrea Mattarei, and Paolo Manfredi synthesized five chemical variants of psilocin designed to release the active molecule into the brain more slowly and steadily . This controlled release aims to preserve therapeutic activity while reducing hallucinogenic effects.

Promising Results in Preclinical Studies

Initial laboratory tests identified compound 4e as the most promising candidate. It demonstrated strong stability during absorption and a gradual release of psilocin. Further testing in mice showed that 4e efficiently crossed the blood-brain barrier, maintaining a sustained presence in the brain comparable to psilocin, but with significantly fewer psychedelic-like behaviors—measured by a reduction in “head twitches” . Despite the reduced behavioral markers of psychedelic activity, 4e continued to strongly interact with key serotonin receptors.

Dissociating Therapeutic Effects from Hallucinations

“Our findings are consistent with a growing scientific perspective suggesting that psychedelic effects and serotonergic activity may be dissociated,” explains Andrea Mattarei, a corresponding author of the study . This dissociation opens the door to designing new therapeutics that retain the beneficial biological activity of psilocybin while minimizing hallucinogenic responses, potentially leading to safer and more practical treatment strategies.

Future Directions and Potential Applications

While these findings are promising, further research is needed to fully understand how these modified psilocin molecules work and to evaluate their safety and therapeutic potential in humans. Researchers believe this “non-trippy” version of the drug could eventually be used to treat a range of conditions, including depression, anxiety, and even neurodegenerative diseases like Alzheimer’s .

Key Takeaways

• Scientists have engineered modified versions of psilocin that reduce hallucinogenic effects while maintaining therapeutic activity.
• Compound 4e showed the most promise in preclinical studies, demonstrating stable absorption, gradual release, and reduced psychedelic-like behaviors in mice.
• These findings suggest that it may be possible to develop psychedelic-inspired medicines without the unwanted “trip.”
• Further research is needed to confirm the safety and efficacy of these compounds in humans.